Studies analyzing the coincidence of cytolysis and thrombotic events in CD59-deficient patients
| First author/reference . | Number of patients . | Clinic . | Thromboembolic events . | Comment . |
|---|---|---|---|---|
| Yamashina46,154 | 1 | Intravascular hemolytic anemia | TE was communicated to have occurred | Untypical presentation in comparison with other patients with CD59 because of lack of polyneuropathy as symptom |
| Nevo,47 Ben-Zeev,48 Mevorach49 | 5 (plus 2 deceased historic cases) | Intravascular hemolytic anemia and polyneuropathy | Two of 7 had fatal cerebrovascular events | Four patients treated with eculizumab |
| Höchsmann50 | 1 | Intravascular hemolytic anemia and polyneuropathy | TE documented | EEculizumab herapy initiated with overall improvement of the patient; within 78 mo after onset of anticomplement therapy no further TE* |
| Haliloglu155 | 3 | Intravascular hemolytic anemia and polyneuropathy | Three of 3 had cerebrovascular events (1 fatal) | EEculizumab herapy initiated with overall improvement of the patient |
| Klemann156 | 1 | Intravascular hemolytic anemia and polyneuropathy | Fatal recurrent cerebrovascular events |
| First author/reference . | Number of patients . | Clinic . | Thromboembolic events . | Comment . |
|---|---|---|---|---|
| Yamashina46,154 | 1 | Intravascular hemolytic anemia | TE was communicated to have occurred | Untypical presentation in comparison with other patients with CD59 because of lack of polyneuropathy as symptom |
| Nevo,47 Ben-Zeev,48 Mevorach49 | 5 (plus 2 deceased historic cases) | Intravascular hemolytic anemia and polyneuropathy | Two of 7 had fatal cerebrovascular events | Four patients treated with eculizumab |
| Höchsmann50 | 1 | Intravascular hemolytic anemia and polyneuropathy | TE documented | EEculizumab herapy initiated with overall improvement of the patient; within 78 mo after onset of anticomplement therapy no further TE* |
| Haliloglu155 | 3 | Intravascular hemolytic anemia and polyneuropathy | Three of 3 had cerebrovascular events (1 fatal) | EEculizumab herapy initiated with overall improvement of the patient |
| Klemann156 | 1 | Intravascular hemolytic anemia and polyneuropathy | Fatal recurrent cerebrovascular events |
Disease: isolated germline encoded homozygous CD59 deficiency (prevalence: too low to calculate). TE, thrombotic event.
From then onward, no further information available (B. Höchsmann, Institute of Transfusion Medicine, University of Ulm, personal communication via email, 12 February 2021).